At Week 3 , aclidinium significantly reduced dyspnea intensity at isotime during exercise ( treatment difference -0.63 ; p < 0.05 ) and improved trough inspiratory capacity ( treatment difference 78 mL ; p < 0.05 ) versus placebo .